Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Amgen Submits Testimony to House Ways & Means Committee
July 10th, 2007
Amgen (NASDAQ:AMGN) today submitted testimony for the record of the House Ways & Means Subcommittee on Health hearing on "Ensuring Kidney Patients Receive Safe and Appropriate Anemia Management Care." Amgen cited data in its testimony showing that the majority of EPOGEN(R) (Epoetin alfa) use in dialysis has been and continues to be appropriate. When examined over time, 83 percent of patient hemoglobin excursions above 12 g/dL fall below 12 g/dL within three months. Amgen also highlighted new analyses of U.S. dialysis data showing that physicians are using EPOGEN even more conservatively since the Centers for Medicare & Medicaid Services (CMS)...
Source: Drug Law Weekly (2007-07-10)
|
